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The neuropeptide Substance P (SP) is an important mediator of neuroimmunomodulatory activity. The aim of this study is to elucidate the
mechanism used by SP to promote increased production of pro-inflammatory cytokines in fresh isolated rat peritoneal mast cells (rPMC). We
have demonstrated that SP induces production of interleukin-6 (IL-6) in rPMC through the PI-3K, p42/44 and p38 MAP kinase pathways.
SP-stimulated rPMC also exhibited an enhanced nuclear translocation of the nuclear factor n B (NFnB). The tumour necrosis factor-a (TNF-
a) and IL-6 production was completely inhibited by using (E)-4-hydroxynonenal (HNE) as an inhibitor of InB-a and -h phosphorylation.
Further, TNF-a and IL-6 expression was significantly inhibited by the oligonucleotides (ODNs) containing the NFnB element (NFnB decoy
ODNs) but not by the scrambled control ODNs. These findings indicate that the NFnB pathway is involved in the transcriptional regulation
of the TNF-a and IL-6 overexpression in primary SP-stimulated mast cells.
D 2003 Elsevier B.V. All rights reserved.Keywords: Mast cell; TNF-a; IL-6; SP; MAPK; NFnB; ODN decoy1. Introduction
Mast cells play a central role in both inflammatory and
allergic reactions through the release of different biological
compounds that are either stored (histamine) or de novo
synthesized (prostaglandins and some cytokines) [1,2]. For
example, the pro-inflammatory cytokines, tumour necrosis
factor-a (TNF-a) and interleukin-6 (IL-6), are produced and
released by activated mast cells [3]. Mast cell activation
occurs via the antigen- or the basic secretagogue-elicited
signalling pathways. As a result of antigen activation, FcqRI
receptors aggregate and initiate a signalling cascade involv-
ing p42/44, p38 and JNK MAP kinases to promote TNF-a
and IL-6 production [4,5]. In the second pathway, it has
been shown that the neuropeptide Substance P (SP), a basic
secretagogue in the family of mast cell agonists, activates
the pertussis toxin-sensitive heterotrimeric GTP-binding
proteins (G proteins) Gi2 and Gi3 [6,7].0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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SP to rat mast cells derived from either uterine, peritoneal
(rPMC) or hypothalamic tissues also promotes TNF-a
production [8–10]. We also had demonstrated that in mast
cells, although only p38 and JNK are involved in TNF-a
production, SP is involved in the activation of the three
main MAP kinases (p42/44, p38 and JNK) [11]. Since TNF-
a and IL-6 promote both beneficial and detrimental effects,
their expression is tightly regulated in many cell types,
including mast cells. The promoter regions of both the TNF-
a and the IL-6 genes contain nuclear factor n B (NFnB),
AP-1, AP-2 and NFAT transcription factor motifs [12,13].
NFnB, the central regulator for the expression of cytokines
involved in the inflammatory response, is commonly found
as a dimer composed of the RelA (p65) and NFnB1 (p50) or
NFnB2 (p52) subunits. The p65 subunit appears to be the
subunit that promotes transcription [14]. NFnB activation
occurs as a result of phosphorylation, polyubiquitination
and proteasome degradation of InB-a and -h. This leads to
the release of activated NFnB, which can then translocate
into the nucleus to activate target genes. In mast cells, while
NFnB has been shown to be activated during FcqRI aggre-
gation, resulting in the production of IL-6 and TNF-a
[15,16], the signalling pathways elicited by SP have not
been identified.
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6 after SP stimulation and we investigated the transcrip-
tional regulatory mechanisms involved in pro-inflammatory
cytokine production. We found that in mast cells, SP
treatment results in the induction of rPMC leading to the
production of TNF-a and IL-6 via NFnB activation.
Further, we have shown that treatment of the cells with
an NFnB decoy oligonucleotide (ODN) completely abro-
gates this induction.2. Materials and methods
2.1. Reagents
Substance P and wortmannin were obtained from Sigma
Aldrich, SB203580 and HNE from Alexis Biochemicals,
PD98059 from New England Biolabs. The NFnB ODN de-
coy [consensus sequence (5VAGTTGAGGGGACTTTCC
CAGGC3V)] and the NFnB scrambled ODN decoy [consen-
sus sequence (5VAGTTGAGGCCACTTTCCCAGGC3V)]
were acquired from Promega. Antibodies: rabbit anti-rat-
IL-6 and -TNF-a antibodies were purchased from Endogen;
rabbit anti-rat NFnB p65 was purchased from Santa Cruz
Biotechnologies; and rabbit anti-h-actin was purchased
from Sigma Aldrich. The antibody against anti-enolase
was the generous gift of Dr. A. Giallongo (Istituto di
Biomedicina e Immunologia Molecolare ‘‘Alberto Mon-
roy’’, C.N.R.).
2.2. Preparation of whole cell and nuclear extracts from
rPMC
The purification, stimulation and pretreatment of
rPMC with inhibitors were performed as described
[11]. Inhibitors were dissolved in dimethylsulfoxide and
diluted with Tyrode’s buffer to the final concentrations,
as indicated in figure legends. The final concentration of
the vehicle in samples was adjusted to 0.1% (v/v); the
control buffer contained the same amount of the vehicle.
For ODN treatment, purified rPMCs were incubated with
4.3 nM NFnB ODNs or scrambled decoy for different
times (15, 30, 60 min) and then stimulated with SP for
30 min.
Nuclear extracts were prepared by lysing 3.5 105 cells
in buffer A (20 mM HEPES pH 7.9, 10 mM NaCl, 0.1 mM
EDTA, 1 mM DTT, 1 mM PMSF, containing 1.5 Ag/ml
aprotinin, pepstatin, leupeptin and chymostatin) for 15 min
on ice. After the addition of Nonidet P-40 (0.5% final
concentration), the cell lysates were centrifuged at
1000 g for 10 min at 4 jC. The pelleted material was
incubated with buffer A supplemented to 550 mM NaCl, for
30 min on ice. Insoluble material was removed by centri-
fugation at 14000 g for 20 min at 4 jC. The protein
concentration of the supernatant was determined using a
standard Bio-Rad protein micro-assay.2.3. Western blot analysis
For TNF-a and IL-6 analysis, identical amounts of
protein (25 Ag) of whole cell extracts were resolved onto
12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE);
for NFnB analysis, cytoplasmic and nuclear extracts (15 Ag)
were resolved onto 10% SDS-PAGE. SDS-PAGE gels were
electro-transferred, probed with antibodies against IL-6,
TNF-a, NFnB p65 and enolase (1:1000 dilution in blocking
solution), and detected by enhanced chemiluminescence
(ECL plusk Amersham Pharmacia Biotech). h-Actin
immunolabeling and Red-Ponceau staining were performed
as loading controls for the cytoplasmic and the nuclear
fractions, respectively. Intensities of protein bands were
quantified by densitometric scanning (Bio-Rad).
2.4. RT-PCR analysis
rPMC (2.5 104) were lysed and mRNA was recovered
by Oligo-dT cellulose (Boehringer Mannheim) as previously
reported [8].
Reverse transcription to generate cDNA was performed
using Advantage RT-PCR kit as recommended by the
supplier (Clontech CA). Competitive-PCR to determine
TNF-a levels of expression was performed as described
using an exogenous internal standard (the standard size is
249 bp) [9,17]. To analyse IL-6 expression, semi-quantita-
tive PCR was performed using IL-6-specific 5Vand 3Vprimers
(5VTAT T G A A A AT C T G C T C T G T T C T 3Vand 5VC
CA C T C C T T C T G TGAC T C TAAC T T C 3V) which
generated a specific band of 233 nucleotides. h-Actin PCR
with specific primers was performed as described [11].
Aliquots of the PCR products (10 Al) were fractionated by
electrophoresis using 1.6% agarose gel containing ethidium
bromide and visualized under UV. The signal intensity was
analysed by computerized densitometry using Molecular
Analysis Software (Bio-Rad). Relative abundance of target
mRNA was estimated after normalization using h-actin
cDNA (175 bp) as an internal standard.
2.5. Statistical analysis
Data were expressed as meanF standard error of the
mean (S.E.) of repeated experiments. One-way analysis of
variance (ANOVA) was used to determine differences
among groups. When differences were determined to exist,
ANOVA analysis was followed by a two-tailed Student’s
test with a P value < 0.05 considered significant.3. Results and discussion
3.1. SP induces IL-6 production by rPMC
Resting mast cells lack expression of IL-6 but become
capable of IL-6 production following IgE-dependent stim-
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production of IL-6 after SP induction. Purified peritoneal
mast cells were challenged with different SP concentra-
tions (0.01, 0.1, 1, 10, 100 AM) and the levels of IL-6
mRNA were quantified by comparison with h-actin
mRNA. The semi-quantitative analysis of the PCR prod-
ucts showed a dose-dependent curve response for IL-6
mRNA levels reaching the maximum after a challenge
with 100 AM SP (Fig. 1A). The time course of IL-6
production by rPMC was also analysed. Mast cells were
activated with 100 AM SP for various times (from 5 to 60
min). Fig. 1B shows an enhancement of IL-6 mRNA
expression beginning at f 15–30 min and reaching the
maximum level of expression after 60 min. In absence of
stimulation, very little IL-6 protein is detected within these
cells, however, it is expressed at high levels and released
after 30 min of SP stimulation (Fig. 1C). These data are in
parallel with our previous results, which showed that, 
 
Fig. 1. SP induces IL-6 production in a dose- and time-dependent manner in rPMC
and RT-PCR was performed to generate IL-6 and h-actin cDNAs. The intensity of
IL-6/h-actin reported. Following stimulation of rPMC with 100 AM SP for differe
using agarose gel analysis of RT/PCR products, and (C) at the protein level in who
immunonoblots of results obtained from three independent experiments are showwhen induced by SP, mast cells also express another
pro-inflammatory cytokine, TNF-a, in a concentration-
and time-dependent manner [9].
3.2. PI-3K, p42/44 and p38 MAPKs are involved in IL-6
production mediated by SP
We have previously demonstrated that in rPMC, SP
activates p42/44, p38 and JNK MAPKs, and that the last
two kinases, but not p42/44, are involved in TNF-a
production [11]. Here, we have investigated whether these
pathways are also involved in SP-induced IL-6 production
by using MAPK-inhibitors. rPMC were treated with the
pharmacological inhibitors of p42/44 (PD98059), p38
(SB203580) or PI-3K (wortmannin) and stimulated with
100 AM SP for 30 min. Wortmannin was used to inves-
tigate the involvement of JNK pathway in IL-6 production,
because it has been shown that in rPMC this inhibitor   
. (A) rPMC were stimulated with different concentrations of SP for 30 min,
the resulting bands was evaluated by densitometry analysis and the ratio of
nt times, IL-6 and h-actin expression was evaluated (B) at the mRNA level
le cell extracts (25 Ag) using Western blot analysis. Representative gels and
n.
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p38 [11]. Addition of PD98059 (50 AM), SB203580 (4
AM) or wortmannin (100 nM) for 30 min resulted in a
partial decrease in the levels of IL-6 mRNA and protein
(Fig. 2A and B). A complete inhibition of IL-6 mRNA
expression was observed after 60 min of pre-incubation
with PD98059, wortmannin and SB203580 inhibitors. The
fact that inhibition was obtained with each of these agents
(SB203580, PD98059 and wortmannin) suggests that at
least three different signalling pathways are involved in IL-
6 production following treatment with SP. Similarly, it has
been shown that FcqRI aggregation in bone marrow-
derived mast cells (BMMCs) involves these three path-
ways, p42/44, JNK and p38 MAPK, for IL-6 production
[5].Fig. 2. Inhibition of p42/44, p38 MAPKs or PI-3K reduces IL-6 production. (A) rP
pretreatment with 50 AM PD98059 (lanes 3 and 4), with 4 AM SB203580 (lanes 5 a
actin mRNA expression levels, RT/PCR was performed. (B) rPMC were stimulate
PD98059 (lane 3), with 4 AM SB203580 (lane 4) or with 100 nM wortmannin (l
determined using Western blot analysis, and representative gel and immunoblot
experiments are shown with *P < 0.05 and **P < 0.01 indicating statistically sign3.3. SP promotes nuclear translocation of NFjB in mast
cells
It has been reported that p38 MAPK and PI-3K are
involved in NFnB activation [19,20]. In addition, in antigen
presenting cells, NFnB is induced by SP to promote pro-
inflammatory cytokine production [21]. Since nuclear trans-
location of NFnB is associated with NFnB-dependent gene
expression, we investigated whether SP induced NFnB
translocation to the nucleus of rPMC. Cytoplasmic and
nuclear extracts of cells induced by SP over a time course
were analysed for the presence of the p65 NFnB subunit. As
shown in Fig. 3, mast cells stimulated with 100 AM SP for
30 min showed an increase of NFnB level in the nuclear
fraction with a corresponding decrease in the cytoplasm.MC were stimulated with 100 AM SP for 30 min following 30 or 60 min of
nd 6) or with 100 nM wortmannin (lanes 7 and 8). To determine IL-6 and h-
d with 100 AM SP for 30 min following 30 min of pretreatment with 50 AM
ane 5). h-Actin and IL-6 protein levels in whole cell extracts (25 Ag) were
s are shown. The meanF S.E. of values obtained from three independent
ificant differences determined in these experiments.
      
Fig. 3. SP elicits NFnB p65 translocation into the nucleus in rPMC. Cytoplasmic and nuclear extracts (15 Ag) from cells stimulated with 100 AM SP at different
time points, following treatment with or without 50 nM HNE, were analysed by Western blot. Immunoblotting was performed and followed by anti-NFnB p65,
anti-h-actin and anti-enolase antibody detection, with Red-Ponceau staining serving as a loading control for the nuclear fraction. Representative immunoblots
are shown. The meanF S.E. of values obtained from three independent experiments are shown with *P < 0.05 and **P < 0.01 indicating significant differences.
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noblotting with anti-h-actin were performed to confirm
equal loading of the protein samples of nuclear and cyto-
plasmic fractions, respectively. Immunoblotting with anti-
enolase antibody served as a marker for cytoplasmic con-
tamination of the nuclear fraction. These results demonstrate
that SP promotes the translocation of p65 from the cyto-
plasm to the nucleus and suggest that NFnB may be a
positive regulator of SP-induced cytokines production in
rPMC, as has been proposed for murine macrophages [22].
3.4. NFjB nuclear translocation is required for SP-induced
TNF-a and IL-6 expression in mast cells
Because NFnB plays a critical role in TNF-a and IL-6
genes expression after FcqRI-stimulation in mast cells
[15,16], we investigated to determine if NFnB nucleartranslocation is associated with SP-induced TNF-a and
IL-6 production in rPMC, using (E)-4-hydroxynonenal
(HNE). HNE prevents NFnB activation and, in turn, pre-
vents nuclear translocation, through selective blocking of
signalling events required for InB-a and -h stimulus-depen-
dent phosphorylation [23]. We confirmed that in our cell
system, HNE inhibits the SP-mediated NFnB nuclear trans-
location (Fig. 3, lane 4); therefore, we analysed the effects
of HNE on TNF-a and IL-6 mRNAs expression by RT-
PCR. Treatment with 50 nM HNE, added 15, 30 or 60 min
before SP stimulation, resulted in a time-dependent decrease
of cytokines production (Figs. 4A and 5A) with maximum
inhibition of SP-induced TNF-a and IL-6 expression after
30- or 60-min drug pre-incubation, respectively. These
results are consistent with published data which show
reduced TNF-a expression in LPS-stimulated human mono-
cytic cells following HNE treatment [23].
 Fig. 4. Inhibition of NFnB nuclear translocation abolishes TNF-a production. (A) rPMC were stimulated with 100 AM SP for 30 min after pretreatment with 50
nM HNE for 15, 30 or 60 min. Competitive RT-PCR was performed to determine the level of TNF-a mRNAs expression in each cDNA samples, which
included 2 103 molecules of TNF-a competitor. Following densitometry analysis, resulting products were quantified by calculating the ratio between the
target and the competitor, with h-actin cDNAs serving as a control for sample extraction. (B) rPMC were stimulated with 100 AM SP for 30 min and pre-treated
with or without 50 nM HNE for 30 min. Western blot analysis of whole cell extracts (25 Ag) was performed using anti-TNF-a and anti-h-actin antibodies. A
representative gel, and immunoblots are shown. The meanF S.E. of values obtained from three independent experiments are shown with **P< 0.01 indicating
significant differences.
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abolishment of SP-induced TNF-a and IL-6 production
following treatment with the NFnB inhibitor, while basal
expression of TNF-a and IL-6 proteins was not affected by
HNE treatment (Figs. 4B and 5B). As has been proposed for
SP-induced antigen presenting cells, the inhibitory effect of
HNE on TNF-a and IL-6 production following SP stimula-
tion in rPMC suggests that NFnB nuclear translocation is
required for the expression of these cytokines [22]. Simi-
larly, the inhibition of NFnB nuclear translocation by the
anti-allergic drug, histaglobin, results in the down-regula-
tion of these pro-inflammatory cytokines in bone marrow-
derived macrophage cells [24].
3.5. NFjB decoy ODNs inhibit the expression of TNF-a and
IL-6 mRNAs induced by SP
In order to determine the role of the NFnB-DNA binding
in SP-activated rPMC, we examined the effect of NFnBdecoy ODNs on TNF-a and IL-6 expression induced by SP.
Use of ODNs as a therapeutic approach has been investigated
recently, because these oligonucleotides, which mimic the
consensus sequences of specific transcription factors (such as
NFnB), hamper the expression and thereby the functionality
of legitimate target genes [25]. Mast cells take up ODN decoy
sequences through a pinocytotic mechanism [26] and this
strategy has been used here to down-regulate NFnB activity.
In this study, treatment of rPMC with an NFnB consensus
sequence ODN decoy at 4.3 nM in cellular suspension caused
a significant time-course-dependent inhibition of SP-induced
TNF-a and IL-6 production. A complete reduction of the SP-
induced production of both cytokines was observed after 60
min of treatment (Fig. 6, lanes 5). A control NFnB decoy
(scrambled sequence) at 4.3 nM did not affect cytokines
production (Fig. 6, lanes 6). Further, the NFnB decoys were
non-toxic, in so far that they did not induce histamine release
from rPMC (data not shown). These findings demonstrate
that NFnB is required for cytokines synthesis in rPMC
Fig. 5. Inhibition of NFnB nuclear translocation abolishes IL-6 production. (A) rPMC were exposed to 50 nM HNE for different lengths of time and stimulated
with 100 AM SP for 30 min. RT-PCR analysis was performed to determine IL-6 and h-actin mRNAs expression levels. (B) rPMC were stimulated with 100 AM
SP for different times after treatment with 50 nM HNE for 30 or 60 min. Western blot analysis of whole cell extracts (25 Ag) was performed using anti-IL-6 and
anti-h-actin antibodies. A representative gel and immunoblots are shown. The meanF S.E. of values obtained from three independent experiments are shown
with **P< 0.01 indicating significant differences.
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abolished their production.
3.6. Concluding remarks
In the present study, we demonstrate that SP induces
IL-6 expression in rPMC in a concentration- and time-
dependent manner as we have already reported for TNF-a
[9]. The signalling pathway activated in mast cells and
leading to the production of cytokines depends on the
stimulus and on the cell type used. By using PD98059,
SB203580 and wortmannin as p42/44, p38 and PI-3K
inhibitors, respectively, we demonstrate that these path-
ways are involved in SP-stimulated IL-6 production. Since
we have previously demonstrated a link between PI-3K
and JNK pathway [11], we conclude that SP induces IL-6
production by activation of p42/44, p38 and JNK MAPK
pathways, similar to FcqRI aggregation in BMMCs [5].TNF-a and IL-6 gene promoters have consensus sequen-
ces targeted by different transcription factors, which are
activated by MAPKs. However, little is known about the
transcription factors activated by MAPKs in SP-challenged
peritoneal mast cells. Studies with FcqRI-stimulated RBL-
2H3 mast cell lines and BMMCs showed that TNF-a [15]
and IL-6 [16] are produced through NFnB. Likewise our
results demonstrate that SP can induce NFnB activation-
translocation in peritoneal mast cells. In our cellular system,
HNE impairs NFnB nuclear translocation, and consequently
we observed a complete block of TNF-a and IL-6 mRNAs,
and proteins increase upon SP stimulation. Moreover, after
blocking of NFnB-DNA binding by ODN decoys, we
confirmed a pivotal role for this transcription factor in
peritoneal mast cells production of SP-stimulated cytokines.
Recent studies have suggested that the regulation of NFnB
activity can occur not only as a result of InB degradation and
the subsequent nuclear translocation of NFnB, but also due
  
Fig. 6. Effects of NFnB decoy on IL-6 and TNF-a expression induced by SP. rPMC were treated with or without NFnB decoy at a 4.3 nM final concentration
for 15, 30 or 60 min and stimulated with 100 AM SP for 30 min. As a control, cells were treated with 4.3 nM scrambled ODN final concentration for 60 min.
RT-PCR analysis of the IL-6 and TNF-a mRNAs was performed as described and representative gels are shown. The meanF S.E. of values obtained from
three independent experiments are shown with **P < 0.01 indicating significant differences.
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activity can also be regulated at the transactivation step by
p38 and p42/44 MAPKs, without affecting InB degradation,
NFnB nuclear translocation or NFnB-DNA binding [5]. Our
data show that in rPMC SP induces NFnB nuclear translo-
cation, however, we have not excluded the possibility that
regulation at the transactivation step may also occur.
Increased levels of pro-inflammatory cytokines have
been associated with a number of neuro-immune disorders,
and elevated levels of SP have often been found in these
diseases [28]. The role of MAPKs and NFnB in these
disorders has been poorly investigated, but it may be
speculated that their activation provides a link between SP
and the increased levels of cytokines that are observed inthese disorders. If this is indeed the case, then drugs
targeting these MAPKs and/or the NFnB pathways might
afford a new target for therapy in SP-correlated neuro-
immune disorders. It is of note that the lack of observed
side effects, when using an NFnB decoy strategy in mast
cells, suggests it as an attractive tool for new drugs designed
to treat neurogenic inflammation.Acknowledgements
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